Skip to NavigationSkip to content

J&J buy global rights to Yuhan's lazertinib in deal worth $1.2bn

Published on 06/11/18 at 10:04am

Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan's third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal worth up to $1.2 billion.

The deal will see J&J pay the South Korean firm $50 million upfront, while the company may pay $1.2 billion in total if commercial and developmental milestones are met. Double digit royalties on sales may also bolster Yuhan’s purse.

The partnership will see Jannsen assume responsibility for the development, manufacture and commercialisation of lazertinib for the treatment of small cell lung cancer (NSCLC) in all global markets outside of South Korea.

Both companies are set to launch global studies looking into the safety and effectiveness of the drug, next year. However Yuhan have already begun studying the drug in South Korea.

Yuhan CEO Lee Jung-hee, commented:“Janssen boasting outstanding expertise in developing anticancer drugs would become our best strategic partner. With the partnership, we will accelerate development of the treatment to improve lives of lung cancer patients.”   

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches